TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Claritev Corporation (CTEV)

Healthcare Health Information Services
22.70 $
-3.7% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Claritev Corporation.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 3 of our scanner strategies — each hit links to the scanner.

Quality & Balance Sheet
Breakout & Setup
Momentum & Trend

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Trading Day

Previous Close
23.60$
Open
23.90$
Day High
24.60$
Day Low
22.70$
Volume
72,853shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
13.50 $ 72.60 $
02/27/2026 08/26/2025

Current price 22.70 $ — 16% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
0.4$B
Shares Outstanding
17Mio.
Float
33.8%
Beta
0.7

Performance

Perf. 1M
37.70%
Perf. 3M
117.60%
Perf. 6M
-20.80%
YTD Performance (%)
-29.70%
52-Week-High Distance
-53.1%
Perf. 1Y
-43.04%
Perf. 3Y
-73.59%
Perf. 5Y
-92.95%
Perf. Since Inception
-94.16%

Technical Indicators

MA 38 Days
29.20$
MA 50 Days
28.10$
MA 200 Days
31.40$
RSI (14)
35.7
Volatility 30 Days
80.6%
Volatility 250 Days
127.7%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
Forward P/E
4.1
PEG
P/B
0.2
P/S
0.4
EV/EBITDA
10.8
Price/FCF

Profitability

Gross Margin
73.2%
EBIT Margin
Net Margin
-29.3%
Return on Equity
-646.3%
Return on Assets
1.1%

Balance Sheet & Safety

Equity Ratio
negative equity
Debt/Equity
-19.1
Altman Z″
1.68
Piotroski
5 out of 9

Growth

Sales Growth Last Quarter
5.80%
EPS Growth Last Quarter
0.00%
Sales Growth (Year)
3.74%
Forward Sales Growth
4.53%
Forward EPS Growth
22.60%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
3
RS Rating
61
EPS Rating
42
Piotroski
5 out of 9
Fundamental Rating
D (38 out of 100)
Altman Z″
1.68

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 22.70 $
Price Target (average) 37.67 $

The price target sits 65.9% above the current price.

Consensus
Hold
Analyst Ratings
2
Distribution of Recommendations
Strong Buy 0
Buy 1
Hold 1
Sell 0
Strong Sell 0

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 5.58 5.58 – 5.58 993 144.3% 1
12/31/2027 6.84 6.84 – 6.84 1,038 22.6% 1

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Next Reporting Date

7. Aug 2026 · before the open · Q2 2026
Expected Earnings per Share
-4.10 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 232.1 $M Q4 2025: Q1 · 231.3 $M Q1 2025: Q2 · 241.6 $M Q2 2025: Q3 · 246.0 $M Q3 2025: Q4 · 246.6 $M Q4 2026: Q1 · 244.7 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -8.09 232 -4.90 -59.40 -34 -65
2025: Q1 -4.18 231 -1.40 -30.80 -30 -69
2025: Q2 -3.67 242 3.50 -25.90 61 37
2025: Q3 -4.09 246 6.70 -28.40 20 -16
2025: Q4 -4.73 247 6.20 -32.70 66 36
2026: Q1 -4.31 245 5.80 -30.10 -46 -95
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Annual Figures

Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2018 1,041 428 36 1.32 292
2019 983 368 10 0.35 284 1,985 8,360
2020 938 -132 -521 -44.23 377 2,558 8,284
2021 1,118 386 102 6.27 405 2,345 8,220
2022 1,080 -363 -573 -35.87 372 1,791 7,371
2023 962 162 -92 -5.69 172 1,709 6,965
2024 931 -1,390 -1,646 -101.92 108 84 5,151
2025 965 45 -284 -17.30 117 -174 4,888

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

About the Company

Claritev Corporation bietet zusammen mit seinen Tochtergesellschaften Datenanalyse und technologiegestützte End-to-End-Lösungen für Kostenmanagement, Zahlung und Erlösintegrität für die Gesundheitsbranche in den USA an. Das Unternehmen bietet Lösungen zur Schadensintelligenz, darunter referenzbasierte P…

Employees3,000
HeadquartersMcLean, VA
Address7900 Tysons One Place, 22102 McLean, United States
Phone212 780 2000
Websiteclaritev.com
IPO Date3. Apr 2020
ISINUS62548M2098
Stock Split1:40 on 09/23/2024

Management

Management
Name Title Birth Year
Travis S. Dalton CEO, President & Chairman 1971
Douglas M. Garis Executive VP & CFO 1985
Jerome W. Hogge III Executive VP & COO 1966
Michael C. Kim Executive VP & Chief Digital Officer 1966
Tiffani D. Misencik Senior VP & Chief Growth Officer 1973
Brock Albinson Senior VP & Chief Accounting Officer 1975
Jason Wong Senior Vice President of Treasury & Investor Relations 1971
Tara A. O'Neil Chief Legal Officer 1966
Kristen Lambert-Kennedy Chief Compliance & Chief Privacy Officer
Melissa Humphrey Senior Vice President of Marketing & Communications

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?